Consumer medicine information

Endometrin Pessaries

Progesterone

BRAND INFORMATION

Brand name

Endometrin

Active ingredient

Progesterone

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Endometrin Pessaries.

SUMMARY CMI

ENDOMETRIN® Pessaries

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using ENDOMETRIN?

ENDOMETRIN contains the active ingredient progesterone, a naturally occurring sex hormone. It is given to women who need extra progesterone while undergoing fertility treatment in an Assisted Reproductive Technology (ART) programme (e.g. In Vitro Fertilisation (IVF)).

For more information, see Section 1. Why am I using ENDOMETRIN? in the full CMI.

2. What should I know before I use ENDOMETRIN?

Do not use ENDOMETRIN if you have ever had an allergic reaction to any medicine containing progesterone or any of the ingredients listed at the end of the CMI, see Section 7. Product details.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. For more information, see Section 2. What should I know before I use ENDOMETRIN? in the full CMI.

3. What if I am taking other medicines?

Tell your doctor, or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with ENDOMETRIN and affect how it works. For more information, see Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use ENDOMETRIN?

The usual dosage is one 100 mg pessary (vaginal tablet) placed directly into the vagina two or three times daily, depending on your needs, following egg retrieval. Your doctor or pharmacist will tell you when to start using ENDOMETRIN and how many tablets you need to use each day.

More instructions can be found in Section 4. How do I use ENDOMETRIN? in the full CMI.

5. What should I know while using ENDOMETRIN?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using ENDOMETRIN.
  • Tell your doctor immediately if you experience pain in your calves or chest, sudden shortness of breath, coughing blood, severe headache or vomiting, faintness or changes in vision or speech, weakness or numbness of an arm or leg and worsening depression while using ENDOMETRIN.
Things you should not do
  • Do not stop using this medicine suddenly or lower the dosage, without checking with your doctor.
  • Do not give your medicine to anyone else, even if they have the same condition as you.
Driving or using machines
  • ENDOMETRIN may cause dizziness in some people.
  • Be careful before you drive or use any machines or tools until you know how ENDOMETRIN affects you.
Looking after your medicine
  • Store it in a cool dry place, where the temperature stays below 25°C, away from moisture, heat or sunlight. Keep this medicine in its original packaging until it is time to use them.

For more information, see Section 5. What should I know while using ENDOMETRIN? in the full CMI.

6. Are there any side effects?

All medicines can have side effects. Most of them are minor and temporary but some may need medical attention.

Tell your doctor if you experience any side effects, including rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or difficulty breathing. These are very serious side effects. You may need urgent medical attention.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

ENDOMETRIN® Pessaries

Active ingredient: Progesterone


Consumer Medicine Information (CMI)

This leaflet provides important information about using ENDOMETRIN. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using ENDOMETRIN.

Where to find information in this leaflet:

1. Why am I using ENDOMETRIN?
2. What should I know before I use ENDOMETRIN?
3. What if I am taking other medicines?
4. How do I use ENDOMETRIN?
5. What should I know while using ENDOMETRIN?
6. Are there any side effects?
7. Product details

1. Why am I using ENDOMETRIN?

ENDOMETRIN contains the active ingredient, progesterone, a naturally occurring sex hormone. It is given to women who need extra progesterone while undergoing treatment in an Assisted Reproductive Technology (ART) programme (e.g. IVF).

Progesterone acts on the lining of the uterus (womb) and it helps you to become pregnant and maintain pregnancy when you are treated for infertility.

ENDOMETRIN is available as a pessary (vaginal tablet).

Ask your doctor if you have any questions about why ENDOMETRIN has been prescribed for you. Your doctor may have prescribed ENDOMETRIN for another reason.

This medicine is available only with a doctor's prescription.

2. What should I know before I use ENDOMETRIN?

Warnings

Do not use ENDOMETRIN if:

  • you are allergic to progesterone, or any of the ingredients listed at the end of this leaflet. Your doctor should make you aware of the signs and symptoms that may indicate an allergic reaction when using ENDOMETRIN.
  • you have or have had any of the following conditions:
    - unusual vaginal bleeding that has not been evaluated by your doctor
    - miscarriage, missed abortion or ectopic pregnancy (pregnancy outside of the womb)
    - severe liver problems
    - known or suspected cancer of the breast or genital tract
    - blood clots in the legs, lungs, eyes or elsewhere in the body
    - porphyria disorder (a blood disease).
  • the expiry date printed on the pack has passed
  • the packaging is torn or shows signs of tampering.

Always check the ingredients to make sure you can use this medicine.

Check with your doctor if you:

  • have any other medical conditions
  • take any medicines for any other condition
  • are not sure whether you should use this medicine.

Other medical conditions you need to tell your doctor about include:

  • epilepsy
  • migraine
  • asthma
  • heart, liver or kidney disease
  • diabetes
  • history of depression.

During treatment, you may be at risk of developing certain side effects.

It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

During fertility treatment ENDOMETRIN should only be used during the first three months of pregnancy, unless your doctor has recommended otherwise.

Check with your doctor if you are pregnant or intend to become pregnant.

The exposure to external progesterone during pregnancy has not been fully established.

Do not use ENDOMETRIN if you are breast-feeding.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with ENDOMETRIN and affect how it works.

Medicines that may increase the effect of ENDOMETRIN include:

  • ketoconazole (medicine for fungal infection), antifungal medicine

Medicines that may reduce the effect of ENDOMETRIN include:

  • rifampicin (antibacterial medicine for tuberculosis, leprosy and some bacterial infections)
  • carbamazepine (medicine for epilepsy)
  • St John's Wort (Hypericum perforatum - a herbal product ingredient)

ENDOMETRIN should not be used at the same time as other vaginal preparations (such as antifungal products).

Your doctor or pharmacist has more information on medicines to be careful with or avoid while are you using this medicine.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect ENDOMETRIN.

4. How do I use ENDOMETRIN?

How much to use

Your doctor or pharmacist will tell you when to start and how many tablets you need to use each day.

  • The usual dosage is one 100 mg tablet placed directly into the vagina two or three times daily, depending on your needs, following egg retrieval. Your doctor will advise you of the appropriate dose for you.
  • Follow the instructions provided and use ENDOMETRIN until your doctor tells you to stop.

When to use ENDOMETRIN

  • ENDOMETRIN should be used following egg retrieval
  • The use of ENDOMETRIN may be continued for up to 10 weeks total duration if pregnancy is confirmed (or 12 weeks of gestation).

How to use ENDOMETRIN

ENDOMETRIN vaginal tablets are intended to be placed directly into the vagina.

An applicator is provided in the pack to help administer the tablets.

Follow the directions on how to administer the tablet below:

  • wash your hands thoroughly with soap and water
  • unwrap the applicator and remove one vaginal tablet from the blister pack
  • put one tablet in the space provided at the end of the applicator. The tablet should fit securely and not fall out
  • the applicator with the tablet may be inserted into the vagina while you are standing, sitting, or when lying on your back with your knees bent. Gently insert the thin end of the applicator well into the vagina
  • push the plunger to release the tablet
  • remove the applicator and rinse it thoroughly in warm running water, wipe dry with a soft tissue and keep the applicator for subsequent use.

The directions on how to administer the tablet are also provided with each pack of ENDOMETRIN.

If you do not understand the instructions, ask your doctor or pharmacist for help.

If you forget to use ENDOMETRIN

ENDOMETRIN should be used regularly at the same time each day.

If you miss your dose at the usual time:

  • If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.
  • Otherwise, use it as soon as you remember, and then go back to using your medicine as you would normally.

Do not use a double dose to make up for the dose you missed.

If you are not sure what to do, talk to your doctor or pharmacist.

If you have trouble remembering to use your medicine, ask your pharmacist for some advice.

If you stop using ENDOMETRIN

Please consult your doctor or pharmacist for advice if you intend to stop or have stopped using ENDOMETRIN.

If you stop using ENDOMETRIN suddenly, you may experience increased anxiety, moodiness and increased sensitivity to seizures.

If you use too much ENDOMETRIN

If you think that you have used too much ENDOMETRIN, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using ENDOMETRIN?

Things you should do

Call your doctor straight away if you experience:

  • pains in your calves or chest, a sudden shortness of breath or coughing blood indicating possible clots in the legs, heart or lungs
  • severe headache or vomiting, dizziness, faintness or changes in vision or speech, weakness or numbness of an arm or leg indicating possible clots in the brain or eye
  • worsening symptoms of depression.

Remind any doctor dentist or pharmacist you visit that you are using ENDOMETRIN.

Things you should not do

  • Do not stop using this medicine suddenly or lower the dosage, without checking with your doctor or pharmacist.
  • Do not give ENDOMETRIN to anyone else, even if they have the same condition as you.
  • Do not use ENDOMETRIN to treat any other complaints unless your doctor has told you to.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how ENDOMETRIN affects you.

ENDOMETRIN may cause dizziness or drowsiness in some people.

Make sure you know how you react to ENDOMETRIN before you drive a car, operate machinery or do anything else that could be dangerous if you are dizzy or light-headed. If this occurs, do not drive.

Looking after your medicine

Keep this medicine in its original packaging until it is time to use it.

Follow the instructions in the carton on how to take care of your medicine properly.

Store it in a cool dry place where the temperature stays below 25°C away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines

When to discard your medicine

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date located on the carton. The expiry date refers to the last day of that month.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Side effects

Side effectsWhat to do
Common side effects (affect more than 1 in 100 users):
  • Headache
  • Abdominal distension (bloating or swelling in the abdomen)
  • Abdominal pain
  • Nausea
  • Vulvovaginal disorders (such as discomfort, burning sensation, discharge, dryness and bleeding)
  • Uterine cramping
Uncommon side effects (affect less than 1 in 100 users):
  • Dizziness
  • Insomnia (difficulty sleeping)
  • Diarrhoea
  • Constipation
  • Urticaria (allergic rash)
  • Rash
  • Fungal infections in the vagina (e.g. vaginal thrush)
  • Breast disorders (e.g. breast pain, breast swelling and breast tenderness)
  • Itching in the genital area
  • Swelling of the limbs (due to fluid build-up)
Unknown frequency:
  • Fatigue (tiredness)
  • Vomiting
These side effects are not usually serious but can become serious.

Speak to your doctor if you have any of these side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
Allergic reactions (unknown frequency):
  • Rash, itching or hives on the skin
  • Swelling of the face, lips, tongue or other parts of the body
  • Shortness of breath, wheezing or difficulty breathing
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What ENDOMETRIN contains

Active ingredient
(main ingredient)
100 milligrams of progesterone (micronised)
Other ingredients
(inactive ingredients)
Colloidal anhydrous silica, lactose monohydrate, pregelatinised maize starch, povidone, adipic acid, sodium bicarbonate, sodium lauryl sulfate, magnesium stearate

Do not take this medicine if you are allergic to any of these ingredients.

What ENDOMETRIN looks like

This medicine is a vaginal tablet.

ENDOMETRIN is a white to off-white, convex and oblong tablets with the inscriptions "FPI" on one side and "100" on the other side.

It is supplied in blister strips packaged in an outer carton. Each carton contains 21 tablets and one vaginal applicator.

(AUST R 189948).

Who distributes ENDOMETRIN

ENDOMETRIN is distributed in Australia by:

Ferring Pharmaceuticals Pty Ltd
Suite 2, Level 1, Building 1,
20 Bridge Street, Pymble NSW 2073

This leaflet was prepared in June 2022.

DOCS #30117-v2D

Published by MIMS November 2022

BRAND INFORMATION

Brand name

Endometrin

Active ingredient

Progesterone

Schedule

S4

 

1 Name of Medicine

Endometrin Pessaries progesterone 100 mg vaginal tablets.

2 Qualitative and Quantitative Composition

Endometrin Pessaries (vaginal tablets) contain 100 mg progesterone (micronised) and also the following excipients: colloidal anhydrous silica, lactose monohydrate, pregelatinised maize starch, povidone, adipic acid, sodium bicarbonate, sodium lauryl sulfate, magnesium stearate.

3 Pharmaceutical Form

Pessaries.
Progesterone is a white or almost white, crystalline powder or colourless crystals which is practically insoluble in water, freely soluble in ethanol, sparingly soluble in acetone and in fatty oils.

4 Clinical Particulars

4.1 Therapeutic Indications

Endometrin Pessaries are indicated for luteal support as part of an assisted reproductive technology (ART) treatment programme for infertile women.

4.2 Dose and Method of Administration

The dose of Endometrin Pessaries is 100 mg administered vaginally three times daily starting at oocyte retrieval and continuing for up to 10 weeks total duration (or 12 weeks of gestation).
Endometrin administered into the vagina BID and TID dosing have both been shown to be efficacious. However specific populations may derive greater benefits from BID or TID dosing regimen and the clinician can tailor treatment to the patient. For women < 35 years of age and those patients with adequate ovarian reserve, Endometrin BID would be the appropriate dose. For patients aged 35 and older and those with diminished ovarian reserve, TID dosing would be the preferred regimen. Serum progesterone levels may be measured 7 days postfertilisation and used to guide therapy.
Endometrin is to be placed directly into the vagina by the applicator provided.
1. Unwrap the applicator.
2. Put one tablet in the space provided at the end of the applicator. The tablet should fit securely and not fall out.
3. The applicator with the tablet may be inserted into the vagina while you are standing, sitting or when lying on your back with your knees bent. Gently insert the thin end of the applicator well into the vagina.
4. Push the plunger to release the tablet.
5. Remove the applicator and rinse it thoroughly in warm running water, wipe dry with a soft tissue and keep the applicator for subsequent use.

4.3 Contraindications

Endometrin Pessaries should not be used in individuals with any of the following conditions:
Hypersensitivity to progesterone or to any of the excipients.
Undiagnosed vaginal bleeding.
Known missed abortion or ectopic pregnancy.
Severe hepatic dysfunction or disease.
Known or suspected breast or genital tract cancer.
Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
Porphyria.

4.4 Special Warnings and Precautions for Use

Endometrin Pessaries should be discontinued if any of the following conditions are suspected: myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis.
Use with caution in patients with mild to moderate hepatic dysfunction.
Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.
Because progesterone may cause some degree of fluid retention, conditions that might be influenced by this factor (e.g. epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation.
A decrease in insulin sensitivity and thereby in glucose tolerance has been observed in a small number of patients on oestrogen-progestogen combination drugs. The mechanism of this decrease is not known. For this reason, diabetic patients should be carefully observed while receiving progesterone therapy.
Sex steroid use may also increase the risk of retinal vascular lesions. To prevent these latter complications, caution is to be taken in users > 35 years, in smokers, and in those with risk factors for atherosclerosis. Use should be terminated in the case of transient ischemic events, appearance of sudden severe headaches, or vision impairments related to papillary oedema or retinal haemorrhage.
Abrupt discontinuation of progesterone dosing may cause increased anxiety, moodiness, and increased sensibility to seizures.
Before starting treatment with Endometrin, the patient and her partner should be assessed by a doctor for causes of infertility.

Use in special populations.

There is no experience with the use of Endometrin in patients with impaired liver or renal function.

Use in the elderly.

No clinical data have been collected in patients over age 65.

Paediatric use.

There is no relevant use of Endometrin in the paediatric population for the indication.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Drugs known to induce the hepatic cytochrome P450 3A4 system (such as rifampicin, carbamazepine and also herbal products containing St. John's wort (Hypericum perforatum)) may increase the elimination rate and thereby decrease the bioavailability of progesterone.
Ketoconazole and other inhibitors of cytochrome P450 3A4 may increase the bioavailability of progesterone.
The effect of concomitant vaginal products on the exposure of progesterone from Endometrin Pessaries has not been assessed. Endometrin is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal tablet.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Endometrin Pessaries are only indicated during the first trimester of pregnancy for use as part of an assisted reproduction (ART) regimen. The effect of Endometrin on fertility has not been evaluated in animals.
(Category A)
There is yet limited and inconclusive data on the risk of congenital anomalies, including genital abnormalities in male or female infants, following intrauterine exposure during pregnancy.
In the pivotal trial, the rate of foetal anomalies following 10 week exposure to Endometrin 100 mg TID was 4.5% in the Endometrin TID group, a total of 7 cases of foetal anomalies (i.e. oesophageal fistula, underdeveloped right ear with hypospadias, small aorta/ valvular regurgitation/ deviated septum, hand deformity, cleft palate/ cleft lip, hydrocephalus and holoprosencephaly/ proboscis/ polydactylia) were seen in 404 patients. The rate of foetal anomalies observed during the clinical trial is comparable with the event rate described in the general population, although the total exposure is too low to allow conclusions to be drawn.
During the conduct of the pivotal clinical trial, the number of spontaneous abortions and ectopic pregnancies associated with the use of Endometrin 100 mg TID were 5.4% and 1%, respectively.
Detectable amounts of progesterone have been identified in the milk of mothers. Therefore, Endometrin should not be used during lactation.

4.7 Effects on Ability to Drive and Use Machines

Endometrin has minor or moderate influence on the ability to drive and use machines. Progesterone may cause drowsiness and/or dizziness; therefore caution is advised in drivers and users of machines.

4.8 Adverse Effects (Undesirable Effects)

The most frequently reported adverse drug reactions during treatment with Endometrin Pessaries in IVF patients during clinical trials are headache, vulvovaginal disorders and uterine spasm, reported in 1.5%, 1.5% and 1.4% subjects, respectively. The table below (Table 1) displays the main adverse drug reactions in women treated with Endometrin in the clinical trial distributed by system organ classes (SOCs) and frequency.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

High doses of progesterone may cause drowsiness.
Treatment of overdose consists of discontinuation of Endometrin Pessaries together with institution of appropriate symptomatic and supportive care.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate oestrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain the pregnancy.

Clinical trials.

A multicentre, randomised, open label phase III study was conducted to determine the efficacy of Endometrin Pessaries 100 mg BID and 100 mg TID administered vaginally in women undergoing IVF and to demonstrate noninferiority of Endometrin versus Crinone 8% vaginal gel (90 mg) once daily (QD).
The primary efficacy variable was ongoing pregnancy following one treatment cycle in the efficacy population. Ongoing pregnancy was defined as identification of fetal heart movement at approximately 6 weeks of gestation. The primary analysis was performed to determine if the ongoing pregnancy rate for each dose of Endometrin was noninferior to the comparator Crinone 8% (90 mg). To declare noninferiority, the lower bound of the 95% confidence interval should exclude a difference greater than 10% in favour of the comparator. Thus, the trial investigated the relative efficacy of Endometrin versus the active comparator Crinone, and used -10% as noninferiority limit based on clinical trials with gonadotrophins used for controlled ovarian stimulation. The absolute efficacy of Endometrin has not been investigated, as trials versus placebo (inactive) have not been conducted. To adjust for multiple comparisons, Endometrin 100 mg TID versus Crinone was considered the primary comparison. If the lower bound of the 95% confidence interval excluded a difference greater than 10% in favour of Crinone, then the noninferiority of Endometrin 100 mg BID versus Crinone was assessed.
A total of 1211 patients undergoing IVF were randomised to receive either Endometrin 100 mg BID (n = 404), Endometrin 100 mg TID (n = 404) or Crinone 8% gel (90 mg) QD (n = 403). Subjects ranged in age from 19 to 42 years. The study drug was initiated on the day after oocyte retrieval and was continued for a total duration of approximately 10 weeks if the patient conceived.
The patient population in this study was also prestratified and randomised according to age (< 35, 35-37, 38-40, 41-42 years). Women up to 35 years of age constituted 61% (N = 737) of the trial population and the majority had FSH levels < 10 IU/L (N = 1047/1193, 88%). The study was powered to demonstrate noninferiority overall for the entire trial population, not for each of the age groups.
The ongoing pregnancy rates in the study were as follows overall, and per age strata. (See Table 2.)
Endometrin 100 mg TID met the noninferiority criterion relative to Crinone 8%, as Endometrin TID was well within the 10% lower bound to demonstrate noninferiority in ongoing pregnancy rate to Crinone 8%. Endometrin BID was just above the 10% lower bound in ongoing pregnancy rate.
Ongoing pregnancy and live birth rates following 10 week luteal support with Endometrin Pessaries are available from the phase III clinical trial. Endometrin 100 mg BID (N = 392) was associated with an ongoing pregnancy rate of 39.8% (95% CI 34.9; 44.9) and a live birth rate of 36.0% (95% CI 31.2; 40.9) in patients who had an embryo transfer. For Endometrin 100 mg TID (N = 390), the ongoing pregnancy and live birth rates in patients with embryo transfer were 43.8% (95% CI 38.9; 48.9) and 39.5% (95% CI 34.6; 44.5), respectively.

5.2 Pharmacokinetic Properties

Absorption.

Progesterone serum concentrations increased following the administration of the Endometrin vaginal tablets in 12 healthy premenopausal females. On single dosing, the mean Cmax of endogenous and exogenous progesterone was 17.0 nanogram/mL in the Endometrin twice daily (BID) group and 19.8 nanogram/mL in the Endometrin three times daily (TID) group.
On multiple dosing, steady state concentrations were attained within approximately 1 day after initiation of treatment with Endometrin. Both Endometrin regimens provided average serum concentrations of progesterone exceeding 10 nanogram/mL on day 5. The pharmacokinetic results are summarised in Table 3.

Distribution.

Progesterone is approximately 96% to 99% bound to serum proteins, primarily to serum albumin and corticosteroid binding globulin.

Metabolism.

Progesterone is metabolised primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolised in the gut via reduction, dehydroxylation, and epimerization.

Excretion.

Progesterone undergoes renal and biliary elimination. Following injection of labelled progesterone, 50-60% of the excretion of metabolites occurs via the kidney; approximately 10% occurs via the bile and faeces. Overall recovery of the labelled material accounts for 70% of an administered dose. Only a small portion of unchanged progesterone is excreted in the bile.

5.3 Preclinical Safety Data

Genotoxicity.

Progesterone did not induce dominant lethal mutations in mice or chromosomal aberrations in the bone marrow of rats in vivo. It did not induce chromosomal aberrations or sister chromatid exchanges in cultured human cells nor chromosomal aberrations or DNA strand breaks in rodent cells. Weak clastogenic activity was found for progesterone in the rat hepatocyte micronucleus test after treatment with a high oral dose (100 mg/kg). Studies on transformation of rodent cells in vitro were inconclusive. Variable results were obtained in the mouse lymphoma tk assay. Progesterone was not mutagenic to bacteria.

Carcinogenicity.

Progesterone has been shown to induce/ promote the formation of ovarian, uterine, mammary, and genital tract tumours in animals. The clinical relevance of these findings is unknown. Literature data provides no indication of potential carcinogenicity in humans. The exposure to women is relatively short and use of progesterone as part of an assisted reproduction regimen (ART) is regarded as replacement therapy.

6 Pharmaceutical Particulars

6.1 List of Excipients

See Section 2 Qualitative and Quantitative Composition.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C.

6.5 Nature and Contents of Container

Endometrin Pessaries containing 100 mg progesterone; white to off-white, convex and oblong tablets with the inscriptions "FPI" on one side and "100" on the other side. Nominal size approximately 22 mm x 13 mm. Supplied in alu/alu blisters packaged in an outer carton. Each carton contains 21 vaginal tablets with 1 vaginal applicator.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

The chemical name for progesterone is pregn-4-ene-3,20-dione.
It has an empirical formula of C21H30O2 and a molecular weight of 314.5.

Chemical structure.

The structural formula of progesterone is:

CAS number.

57-83-0.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes